Sarepta closes enrollment in Elevidys Phase 3 ENVISION trial after more than a year on hold

Sarepta closes enrollment in its Elevidys ENVISION trial after more than a year on clinical hold; plus four states sue over Medicaid work requirements and a real-world study favors Repatha over ezetimibe.